Press Release March 02, 2018

Teva Closes Divesture of Global Women’s Health Franchise for $2.48 Billion

The Life Sciences team advised Teva Pharmaceutical Industries Ltd. as it closed two definitive agreements to sell the remaining assets of its specialty global women’s health business for $1.38 billion. Proceeds from these sales, combined with proceeds from the sale of PARAGARD®, on which Goodwin also advised Teva, total $2.48 billion and will be used by Teva to progress repayment of term loan debt.

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in over 60 markets every day.

For additional details on both closings, please read the press releases here and here.